Artificial Blood: The History and Current Perspectives of Blood Substitutes

Khan, Fahad; Singh, Kunwar P.; Friedman, Mark T.

doi:10.15190/d.2020.1

Cited by 59 publications

(40 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, some HBOCs have shown therapeutic promise in maintaining graft/organ vitality and function, and in minimizing the risk of reoxygenation injuries or IRI [ 18 , 19 ]. Also, considering their additional benefits as potential blood substitutes without the inconvenience of crossmatching, their application in maintaining optimum tissue oxygenation is deemed highly appropriate and is under further investigation [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

“…Interestingly, Hemopure (HBOC-201) has been approved by the South African drug council for the treatment of anemia. Moreover, this product is allowed to be used in United States in qualified patients to treat severe life-threatening anemia under the FDA’s expanded compassionate use access program [ 20 , 26 , 27 , 28 , 29 ]. Additionally, one randomized, multicenter trial investigation of HBOC-201 in non-cardiac surgery patients indicated that its use reduced RBC transfusions in 43% of patients without notable differences in mortality and serious adverse events, though there was a notable increase in the associated non-serious events (i.e., hypertension and fever) [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Potential of Hemoglobin Derived from the Marine Worm Arenicola marina (M101): A Literature Review of a Breakthrough Innovation

et al. 2021

View full text Add to dashboard Cite

Oxygen (O2) is indispensable for aerobic respiration and cellular metabolism. In case of injury, reactive oxygen species are produced, causing oxidative stress, which triggers cell damaging chemical mediators leading to ischemic reperfusion injuries (IRI). Sufficient tissue oxygenation is necessary for optimal wound healing. In this context, several hemoglobin-based oxygen carriers have been developed and tested, especially as graft preservatives for transplant procedures. However, most of the commercially available O2 carriers increase oxidative stress and show some adverse effects. Interestingly, the hemoglobin derived from the marine lugworm Arenicola marina (M101) has been presented as an efficient therapeutic O2 carrier with potential anti-inflammatory, anti-bacterial, and antioxidant properties. Furthermore, it has demonstrated promise as a supplement to conventional organ preservatives by reducing IRI. This review summarizes the properties and various applications of M101. M101 is an innovative oxygen carrier with several beneficial therapeutic properties, and further research must be carried out to determine its efficacy in the management of different pathologies.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic Potential of Hemoglobin Derived from the Marine Worm Arenicola marina (M101): A Literature Review of a Breakthrough Innovation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Alternatively, we approached an oxygenated perfluorodecalin (PFD), a liquid that has a remarkable adsorbing capacity for O 2 and CO 2 to devise liquid-based EVA (l-EVA). Due to its biocompatibility and safety in humans through intra-airway, 11 ocular, 12 and blood 13 infusion, intrapulmonary application of perfluorochemical in liquid or aerosol is already used in clinics to reduce lung injury in pediatric cases of severe respiratory insufficiency. 11 The low surface tension and high density allows perfluorocarbon to serve as surfactant substitutes.…”

Section: Resultsmentioning

confidence: 99%

“…The use of perfluorochemicals is encouraging toward clinical translation because numerous clinical studies with different delivery methods highlight safe and tolerable features in patients. [11][12][13] For example, when an emulsified form of perfluorochemicals was administered directly into the blood vessels or the airway, relatively modest side effects were reported, including the elevation of blood pressure and injury to organs. 12,[17][18][19] The level of arterial oxygenation, if scaled for human application, is likely sufficient to alleviate patients with severe respiratory failure.…”

Section: Discussionmentioning

confidence: 99%

Mammalian enteral ventilation ameliorates respiratory failure

Okabe

Chen‐Yoshikawa

Yoneyama

et al. 2021

Med

View full text Add to dashboard Cite

show abstract

“…Table 1 lists the HBOC products that reached clinical trials. Most of them have been abandoned by now, the research and development (R&D) in this field has new directions (38,39). Nevertheless, HBOC research contributed considerably to the understanding of many aspects of O 2 delivery and circulatory control.…”

Section: Hemoglobion-based Oxygen Carriers and The History Of Failed mentioning

confidence: 99%

The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers

Bedőcs

Szebeni

2020

Front. Immunol.

View full text Add to dashboard Cite

Intravenous injection of nanopharmaceuticals can induce severe hypersensitivity reactions (HSRs) resulting in anaphylactoid shock in a small percentage of patients, a phenomenon explicitly reproducible in pigs. However, there is a debate in the literature on whether the pig model of HSRs can be used as a safety test for the prediction of severe adverse reactions in humans. Given the importance of using appropriate animal models for toxicity/safety testing, the choice of the right species and model is a critical decision. In order to facilitate the decision process and to expand the relevant information regarding the pig or no pig dilemma, this review examines an ill-fated clinical development program conducted by Baxter Corporation in the United States 24 years ago, when HemeAssist, an αα (diaspirin) crosslinked hemoglobin-based O 2 carrier (HBOC) was tested in trauma patients. The study showed increased mortality in the treatment group relative to controls and had to be stopped. This disappointing result had far-reaching consequences and contributed to the setback in blood substitute research ever since. Importantly, the increased mortality of trauma patients was predicted in pig experiments conducted by US Army scientists, yet they were considered irrelevant to humans. Here we draw attention to that the underlying cause of hemoglobin-induced aggravation of hemorrhagic shock and severe HSRs have a common pathomechanism: cardiovascular distress due to vasoconstrictive effects of hemoglobin (Hb) and reactogenic nanomedicines, manifested, among others, in pulmonary hypertension. The main difference is that in the case of Hb this effect is due to NO-binding, while nanomedicines can trigger the release of proinflammatory mediators. Because of the higher sensitivity of cloven-hoof animals to this kind of cardiopulmonary

show abstract

Artificial Blood: The History and Current Perspectives of Blood Substitutes

Cited by 59 publications

References 57 publications

Therapeutic Potential of Hemoglobin Derived from the Marine Worm Arenicola marina (M101): A Literature Review of a Breakthrough Innovation

Therapeutic Potential of Hemoglobin Derived from the Marine Worm Arenicola marina (M101): A Literature Review of a Breakthrough Innovation

Mammalian enteral ventilation ameliorates respiratory failure

The Critical Choice of Animal Models in Nanomedicine Safety Assessment: A Lesson Learned From Hemoglobin-Based Oxygen Carriers

Contact Info

Product

Resources

About